General
Preferred name
LATANOPROSTENE BUNOD
Synonyms
LBN ()
NCX116 ()
BOL-303259-X ()
NCX 116 ()
PF-3187207 ()
Latanoprosteno bunod ()
Vyzulta ()
Vesneo ()
NCX-116 ()
P&D ID
PD059039
CAS
860005-21-6
Tags
available
drug
Approved by
FDA
First approval
2017
Drug indication
Renal cell carcinoma
Open-angle glaucoma
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Latanoprostene bunod is a -donating analogue of the prostaglandin F2α agonist . This compound benefits from the additive hypotensive actions of both the prostaglandin agonist and NO. Latanoprostene bunod is a novel pharmacological candidate being investigated for its ability to treat ocular hypertension .
METABOLISM Upon topical administration at the ocular surface, latanoprostene bunod undergoes rapid carboxyl ester hydrolysis by endogenous corneal esterases into latanoprost acid and butanediol mononitrate [FDA Label].; ; After the latanoprost acid reaches the systemic circulation, it is largely metabolized by the liver to the 1,2-dinor and 1,2,3,4-tetranor metabolites by way of fatty acid beta-oxidation [FDA Label].; ; The butanediol monohidrate undergoes further metabolism (reduction) to 1,4-butanediol and nitric oxide (NO). Furthermore, this 1,4-butanediol metabolite is further oxidized to succinic acid that is subsequently then primarily taken up as a component in the tricarboxylic acid (TCA) cycle in cellular aerobic respiration [FDA Label].
ABSORPTION In a study with 22 healthy subjects monitored for 28 days, there were no quantifiable plasma concentrations of latanoprostene bunod (Lower Limit Of Quantitation, LLOQ, of 10.0 pg/mL) or butanediol mononitrate (LLOQ of 200 pg/mL) post daily dose of one drop bilaterally in the morning on Day 1 and 28 [FDA Label].; ; The mean time of maximum plasma concentration (Tmax) for latanoprost acid was about 5 minutes post dosage on both Day 1 and 28 of therapy [FDA Label].; ; The mean maximum plasma concentrations (Cmax) of latanoprost acid (LLOQ of 30 pg/mL) were 59.1 pg/mL on Day 1 and 28, respectively [FDA Label].
DESCRIPTION Latanoprostene bunod (LBN), a nitric oxide (NO)-donating prostaglandin F2a analog, is a topical ophthalmic therapeutic for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension (OHT) [1].
PRICE 298
DESCRIPTION Latanoprostene bunod is a -donating analogue of the prostaglandin F2α agonist . This compound benefits from the additive hypotensive actions of both the prostaglandin agonist and NO. Latanoprostene bunod is the first NO-donating prostaglandin analogue to be granted FDA marketing approval . (GtoPdb)
DESCRIPTION Latanoprostene bunod (LBN) is nitric oxide (NO)-donating prostaglandin F2a analog and is a topical ophthalmic therapeutic. It is used for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension (OHT). (TargetMol Bioactive Compound Library)
Compound Sets
12
Cayman Chemical Bioactives
25830
ChEMBL Approved Drugs
CHEMBL2364612
ChEMBL Drugs
CHEMBL2364612
DrugBank
DB11660
DrugBank Approved Drugs
DB11660
DrugCentral
5261
DrugCentral Approved Drugs
5261
DrugMAP
DM2EXC5
DrugMAP Approved Drugs
DM2EXC5
Guide to Pharmacology
9635
MedChem Express Bioactive Compound Library
HY-19518
TargetMol Bioactive Compound Library
T15719
External IDs
27
Properties
(calculated by RDKit )
Molecular Weight
507.28
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
3
Rotatable Bonds
18
Ring Count
2
Aromatic Ring Count
1
cLogP
3.77
TPSA
139.36
Fraction CSP3
0.67
Chiral centers
5.0
Largest ring
6.0
QED
0.09
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Prostaglandin Receptor
Pathway
GPCR/G protein
Source data